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Abstract-The need for self-protecting polymer or alloy implants resistant to a broad spectrum of bacterial challenges led us to investigate 
covalent bonding of minocycline (MIN), a tetracycline derivative, to polystyrene beads and to titanium alloy foils by oligoethylene glycol 
spacers. 9-Hydrazino-acetyl-amido-MIN, and simpler glycylcycline derivatives, retained minimum inhibitory concentration (MIC) 
against Staphylococcus aureus comparable to MIN. However, PEG-glycyl-amido-MIN showed very low activity. Hence, we coupled 9-
hydrazino-acetyl-amido-MIN to the aldehyde termini of oligoethylene glycol spacers bonded to polystyrene and titanium alloy surfaces to 
form acid-releasable hydrazone linkages. 9-Hydrazino-acetyl-amido-MIN was released from the monolayers more rapidly at pH 5.0 than 
at pH 7.4. ©2007 Elsevier Science Ltd. All rights reserved. 
Infections are a devastating complication of medical 
implant devices that cause significant morbidity. The 
management of infected implants has serious economic 
implications. For example, in the United States, 
treatment of 3500-4000 cases of knee and hip infections 
every year costs an estimated 150 to 200 million 
dollars1. Because of poor vascularity and biofilm 
formation at the implant sites, such infections have 
proven difficult to prevent or treat. The local application 
of antibiotics is a well-known and accepted therapy for 
such kind of implications2-4. Current practice includes 
antibiotic-impregnated bone cement5, and antibiotic-
containing coating systems6-8. These methods are 
intended to release antibiotics rapidly and irreversibly, 
and require a carrier material other than the orthopaedic 
implant itself to transport the antibiotic materials. Some 
non-resorbable materials used in the methods even need 
to be removed after the surgery9. 
 
Because of the combination of their many 
biocompatible properties, titanium and titanium alloys 
are frequently applied in a wide variety of biomedical 
devices10. In our initial studies11 using fine titanium (Ti) 
particles which had been aminopropylated12,13, we 
utilized the last resort glycopeptide antibiotic 
vancomycin (VAN), which acts at the surface of the 
Gram-positive bacterial cell wall to block peptidoglycan 
synthesis14,15. Hydrophilic bis(ethylene glycol) spacers 
were coupled to the solid phase NH2PrSiO-Ti particles, 
followed by VAN11. The biological results showed that 
the VAN-modified Ti particles effectively inhibited the 
growth of S. aureus compared with control Ti particles 
on which the bacteria grew abundantly11.  
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The strategy was then extended to Ti6Al4V alloy pins, 
widely used for orthopaedic implants16. We found that 
VAN could be covalently linked to the Ti6Al4V alloy 
surface on orthopaedic implants, following oxidation17.  
Covalently bound VAN was retained on the surface for 
an extended period of time and retained significant 
antibiotic activity18. 
 
Most implant infections are caused by Gram-positive 
bacteria19, but some are caused by Gram-negative 
bacteria, which are susceptible to broad-spectrum 
antibacterial agents such as tetracyclines. Bacterial 
resistance to tetracyclines has curtailed their clinical 
effectiveness. A minimum of semisynthesis and 
analoging has been carried out with tetracyclines, 
compared to other classes of antibiotics, perhaps due to 
their complex chemistry, chemical liability, and lack of 
reactivity of the intact naphthacene nucleus. 
  
Glyclcyclines, such as tigecycline, recently approved by 
FDA20, are active against a broad range of Gram-
positive and Gram-negative bacterial strains resistant to 
tetracycline or doxycycline. Tigecycline, however, lacks 
functional groups suitable for connecting to a solid 
support. Minocycline (MIN), on the other hand, allows 
exclusive 9-nitration, the starting point for glycylcycline 
extension.  
 
MIN is effective against a broad range of Gram-positive 
and Gram-negative bacteria21, displaying an MIC of 
0.12 µg/mL against S. aureus22. Against E. faecalis and 
E. faecium, by comparison, MIN was found ~8-fold 
more active than linezolid and 32-fold more than 
quinupristin-dalfopristin23. Bulky groups at the 9-
position of glycylcyclines usually contribute to 
activity24, supporting our strategy of coupling moieties 
to the 9-position of MIN to create new glycylcyclines. 
We therefore chose MIN as the basis for glycylcycline 
tethering to solid surfaces. 
  
Here we report the design and synthesis of several MIN 
C9 derivatives and the determination of their minimum 
inhibitory concentration (MIC). Attachment of the MIN 
derivatives to polystyrene beads and Ti6Al4V alloy 
foils via acid-labile linkers was carried out to 
characterize the bioactivity of the tethered MIN 
derivatives. 
 
We synthesized [4S-(4α,12aα)]-9-H2N-4,7-bis(Me2N)-
1,4,4a,5,5a,6,11,12a-octohydro-3,10,12,12a–
tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (9-
H2N-MIN) as described22. Briefly, to an ice-cold 
solution of MIN·HCl (1 gram, 2.03 mmol) in 9 mL of 
concentrated H2SO4 was added KNO3 (224 mg, 2.4 
mmol). The reaction mixture was stirred at 0˚C for 
about 1.5 hour, and monitored by HPLC on a 150×4.6 
mm Phenomenex® Luna phenyl-hexyl 5 µm column, 
eluted with 25% CH3CN in 35 mM Na2HPO4, pH 7.5, 
on a Waters 600 liquid chromatograph (Milford MA 
USA). When the reaction came to completion, the 
mixture was slowly poured into 240 mL of ice-cold 
Et2O. The precipitate was collected by filtration, and 
washed with Et2O three times. The solid was dried 
overnight under vacuum to give 9-O2N-MIN·(SO4)2. 
The product was characterized by HPLC, showing a 
prominent product peak, and MS of the main peak 
(SELDI-TOF mass spectrometer (Ciphergen, Fremont, 
CA), calc. 502.47 Da, found 502.5 Da. The dried 9-
O2N-MIN·(SO4)2 (1.29 g, 1.8 mmol), 200 mg of 10% 
palladium on charcoal, and 4.5 mL of 2 N H2SO4 in 6 
mL of 2-MeOEtOH were mixed and hydrogenated in a 
Parr apparatus at 40 psi for 1.5 hr. The catalyst was 
filtered and the filtrate was added dropwise to a mixture 
of 2-PrOH (210 mL) and Et2O (150 mL). The yellow 
solid was collected by filtration, washed several times 
with Et2O and dried under vacuum at room temperature 
overnight to yield 1.16 g of 9-H2N-MIN·(SO4)2 (90% 
yield). The product was characterized by HPLC and 
MS: calc. 472.2 Da, found 472.0 Da. 
 
We then converted 9-H2N-MIN into [4S-(4α,12aα)]-9-
[(HNAc)NH]-4,7-bis(Me2N)-1,4,4a,5,5a,6,11,12a-
octohydro-3,10,12,12a–tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide (9-Gly-NH-MIN). To a 
solution of Boc-Gly (458 mg, 1.2 mmol) in 3 mL 
Me2NCHO was added 412 mg of 2-(7-aza-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexa-
fluorophosphate (HATU) (Applied Biosystems, Foster 
City CA, USA)  (1.1 equivalent) and 311 µL of iPr2EtN. 
The reaction mixture was stirred at room temperature 
for 30 min, then mixed with 9-H2N-MIN·(SO4)2 (575 
mg, 0.95 mmol) in 4 mL Me2NCHO. After 1 hr at room 
temperature, the product was precipitated by addition of 
2 volumes of ice-cold Et2O. After sedimentation and 
removal of supernatant, the precipitate was dissolved in 
4 N HCl/dioxane and incubated for 10 min. at room 
temperature to remove the Boc protecting group. The 
final product, 9-Gly-H2N-MIN, was precipitated twice 
from Et2O). MS: calc. 529.54 Da, found 530.1 Da. 
Next, we prepared [4S-(4α, 12aα)]-4, 7-Bis(Me2N)-9-
[(HNAc)NH]-4,7-bis(Me2N)-1,4,4a,5,5a,6,11,12a-
octohydro-3,10,12,12a–tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide (9-hydrazino-Ac-H2N-MIN) 
(Scheme 1). To a solution of N,N,N’-Boc3-
hydrazinoacetic acid (369 mg, 0.95 mmol) in 3 mL 
Me2NCHO was added 397 mg of HATU (1.1 
equivalent) and 264 µl of iPr2EtN. The reaction mixture 
was stirred at room temperature for 30 min, then mixed 
with 9-H2N-MIN·(SO4)2 (600 mg, 0.9 mmol) in 4 mL 
Me2NCHO and 1 g of NaCO3, and stirred for 1 hr at 
room temperature. It was found that the yellow solution 
changed to brown. The solid was removed by filtration 
and the filtrate was applied to a 150×15 mm C18 column 
(WAT 020594, Waters Associates). The column was 
washed with H2O to remove Me2NCHO. Because of the 
strong hydrophobicity of 9-Boc3-hydrazino-Ac-NH-
MIN, the impurities in the reaction mixture could be 
eluted from the C18 column by 20% CH3CN in aqueous 
0.1% CF3CO2H. The product was eluted with pure 
CH3CN, concentrated by rotatory evaporation, and 
lyophilized overnight. The dried sample was dissolved 
in 4 M HCl in dioxane to deprotect the Boc groups. 
After 10 min, a precipitate was formed. The mixture 
was kept at room temperature under shaking. The 
precipitate was collected by filtration and washed with 
Et2O three times. The solid product was dried under 
vacuum to give 510 mg of 9-hydrazino-Ac-H2N-MIN 
·(Cl)2 as a yellow powder (92% yield). The product was 
characterized by HPLC and MS: calc. 544.56 Da, found 
544.6 Da. 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reaction scheme for synthesis of 9-hydrazino-Ac-NH-MIN. 
 
To PEGylate 9-Gly-NH-MIN, we added 1 equivalent of 
HATU and 1.2 equivalent of iPr2EtN to 1 mL 
Me2NCHO containing 100 mg of O-(N-Fmoc-2-
aminoethyl)-O`-(2-carboxyethyl)-undecaethyleneglycol 
(PEG12 carboxylate) (Merck, Darmstadt, Germany)  
stirred at room temperature for 30 min, to which 1.1 
equivalent of 9-Gly-NH-MIN was added. The reaction 
mixture was kept at room temperature for 2 hr under 
stirring. The reaction was stopped by addition of H2O. 
Taking the molecular mass (1351 Da) of 9-PEG12-Gly-
NH-MIN into consideration, we employed a Sephadex 
G-25 column (1.7×30 cm) eluted with aqueous 0.5% 
HOAc to separate the conjugate from the impurities. 
The eluent corresponding to the first peak was collected, 
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concentrated and freeze dried. The dried sample was 
redissolved in H2O, then characterized by HPLC and 
MS: calc. 1351.49 Da, found 1351.6 Da. 9-PEG26-Gly-
NH-MIN was prepared similarly. The product was 
characterized by HPLC and MS: calc. 2056.33 Da, 
found 2056.0 Da. 
 
Measurements of MIC25 for each of the MIN derivatives 
without PEG (Table 1) showed that 9-Gly-NH-MIN and 
9-hydrazino-Ac-NH-MIN retained significant biological 
activity, compared with unmodified MIN. However, the 
MIC of the two 9-PEG-MIN derivatives was 
dramatically elevated. The bulky PEG modification 
might have inhibited bacterial uptake of the MIN 
derivatives, and/or the binding of MIN to the 30S 
ribosomal subunits, resulting in the loss of bioactivity 
by the PEG-MIN derivatives. This result argues against 
permanent PEG tethering of MIN derivatives to medical 
implants. 
 
 
Because of the loss of bioactivity of MIN after 
conjugation with PEG, we selected the acid-liable 
hydrazone bond to link 9-hydrazino-Ac-NH-MIN to 
solid surfaces, so that the drug could be released on 
demand upon acidification of the microenvironment by 
proliferating bacteria26.  
 
Hydrazone bonds have been widely investigated for 
targeting drug delivery27. The bond is relatively stable in 
physiological pH. When the delivered drug was 
absorbed through endocytosis pathway, the hydrazone 
could be broken in response to the low pH in 
cytoplasmic endosomes28. To enable release on demand, 
the hydrazone bonds should remain largely intact for an 
effective number of days after implant insertion. For the 
attachment of antibiotics to the surface of implants by 
acid-labile linkers, we expect that the antibiotics should 
remain stably attached on the surface for weeks to 
months. Due to the reversible property of hydrazone 
bonds in aqueous solution, the antibiotics attached to 
implant surfaces could be released gradually at neutral 
pH, but rapidly at acid pH induced by infection.  
 
We selected TentaGel S-NH2 polystyrene beads as a 
model to investigate the release of 9-hydrazino-Ac-NH-
MIN from a polymeric surface. The amino groups on  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reaction scheme for synthesis of PS-Succ-NHPr-hydrazone-9-
Ac-NH-MIN. 
 
500 mg of TentaGel S-NH2 (Fluka 86364, 0.26 mmol/g) 
resin were transformed to carboxylates by reaction with 
1.5 equivalent of succinic anhydride in the presence of 
0.1 equivalent of N,N-dimethylaminopyridine (DMAP) 
catalyst dissolved in in 4 mL of pyridine (Scheme 2). 
The reaction mixture was kept at 50˚C with shaking for 
3 hr. A ninhydrin test showed no free amino groups 
available on the surface of the resin beads. The 
carboxylates on the resin were activated by HATU and 
iPr2EtN at room temperature for 30 min, then coupled 
with H2NPr(OEt)2 at room temperature for 3 hr. The 
resin was washed with Me2NCHO and CH2Cl2, then 
dried under vacuum. Next, the resin was treated with 
50% CF3CO2H in CH2Cl2 for 30 min to yield aldehyde-
modified resin, which was washed with Me2NCHO and 
CH2Cl2, then dried under vacuum overnight. 9-
Hydrazino-Ac-NH-MIN at 0.1 M in CHCl3 was then 
reacted with the aldehyde termini to yield the acid-labile 
hydrazone-linked 9-Ac-NH-MIN polystyrene beads. 
The resin was washed with physiological buffer (0.15 M 
NaCl, 0.01 M Na2HPO4, pH 7.4, PBS), Me2NCHO and 
CH2Cl2, then dried under vacuum overnight. PS-Succ-
NHPr-hydrazone-9-Ac-NH-MIN resin beads were 
stripped with 10% HOAc in CH2Cl2 to determine the 
total loading of 9-hydrazino-Ac-NH-MIN, 52 µg/g 
resin, by absorbance at 350 nm29.  
 
The stability of the hydrazone bond was investigated by 
incubating 5.6 mg aliquots of PS-Succ-NHPr-
hydrazone-9-Ac-NH-MIN resin beads at 37°C under 
physiological conditions in 1.5 mL of 0.1 M Na2HPO4, 
pH 7.4, and under conditions of anaerobic bacterial 
metabolism in a confined microenvironment in 0.1 M 
NaOAc, pH 5.0. The concentration of the released 9-
hydrazino-Ac-NH-MIN in the buffers was determined 
by absorbance at 350 nm29 (Fig. 1).  
 
Table 1. MIC of MIN derivatives with S. aureus  
Compound MIC 
(found) 
µg/mL 
MIC 
(published) 
µg/mL 
MIN 0.125 0.125 
9-H2N-MIN 2 1 
9-Gly-NH-MIN 2 0.5-1 
9-hydrazino-Ac-NH-MIN 2 NA 
9-PEG12-Gly-NH-MIN 500 NA 
9-PEG26-Gly-NH-MIN 1000 NA 
S. aureus subspecies aureus Rosenbach (ATCC 25923) 
were incubated in Mueller-Hinton broth at 37°C for 14 
hr, noting the dilution midway between fully inhibited 
and uninhibited bacterial proliferation25 
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Figure. 1. Release of 9-hydrazino-Ac-NH-MIN from PS-Succ-NHPr-
hydrazone-9-Ac-NH-MIN resin beads as a function of pH. Solid line: 0.1 
M Na2HPO4, pH 7.4. Dashed line: 0.1 M NaOAc, pH 5.0. 
 
The time course of 9-hydrazino-Ac-NH-MIN release 
from the beads showed much faster release at pH 5.0 
than at pH 7.4. After 24 hr at pH 5.0, released MIN 
reached 36.7 µg/mL, or 54% of the MIN loading 
measured after coupling (Fig. 1). That value is 18 times 
greater than the MIC of 2 µg/mL. After 24 hr at pH 7.4, 
released MIN reached 18.8 µg/mL, or 27.6% of the 
MIN loading measured after coupling The leveling of 
the A350 trace after 24 hr is probably the result of the 
instability of hydrazino-MIN. Hence, the hydrazone 
bond is not stable enough to keep 9-hydrazino-Ac-NH-
MIN on the surface for an extended period of time.  
 
We also attached 9-hydrazino-Ac-NH-MIN to the 
surface of Ti6Al4V foil. We prepared H2NPrSi-O-
Ti6Al4V alloy foil as described previously for Ti6Al4V 
pins17. The amine was then coupled with 4 equivalents 
of glyoxylyl-8-amino-3,5-dioxaoctanoic acid in the 
presence of HATU/iPr2EtN in Me2NCHO. 9-
Hydrazino-Ac-NH-MIN at 0.1 M in CHCl3 was coupled 
to the surface of the aldehyde-PEG-NHPrSi-O-Ti6Al4V 
foil for 4 hr to yield Ti-O-SiPrNH-PEG-hydrazone-9-
Ac-NH-MIN. The foil was washed with CH2Cl2, 
Me2NCHO and double deionized H2O, then dried under 
vacuum overnight. On the surface of a one cm2 
Ti6Al4V foil with a maximum monolayer loading of 
200 pmol30, as we found for VAN18, the amount of 
strippable MIN would be too low to measure by UV 
absorbance. 
 
To determine bacterial viability on Ti6Al4V foil 
substrates, control Ti6Al4V alloy foils and Ti-O-
SiPrNH-PEG-hydrazone-9-Ac-NH-MIN alloy foils 
were sterilized by incubation with 70% EtOH, and 
washed five times with autoclaved PBS. S. aureus 
subspecies aureus Rosenbach were cultured in Mueller-
Hinton broth at 250 rpm, 37°C for 14 hr. Using a 0.5 
McFarland standard, the bacteria were diluted to 1×104 
cfu/mL in Mueller-Hinton broth. The sterilized 
Ti6Al4V foils were cultured with the S. aureus at 37°C 
for 24 hr, after which the pH was still 7.3-7.4. For 
Ti6Al4V foil, we immersed the MIN-bonded foil in the 
minimum volume of 200 µL of broth. The foils were 
washed three times with PBS to remove loosely 
adherent bacteria, and assessed for bacterial adhesion 
and viability by staining with the Live/Dead® 
BacLight™ viability kit, which fluorescently labels 
viable bacteria green and dead bacteria red. After 
labeling, the Ti6Al4V alloy foils were washed three 
times with PBS to remove nonspecific stain and 
visualized by confocal laser fluorescence microscope on 
a Fluoview 300 (Olympus, Melville, NY). Challenge by 
S. aureus, however, showed live bacteria on all foil 
samples. At physiological pH, the concentration of 9-
hydrazino-Ac-NH-MIN that could be released into the 
medium was insufficient to inhibit the growth of S. 
aureus. Even if all the attached monolayer of MIN were 
released into the broth, the resulting MIN concentration 
of 1.2 µg/mL would have been below the MIC of 2 
µg/mL. The flat foil has much less surface area than the 
porous resin beads. 
 
For the construction of medical implants with 
covalently bound broad-spectrum antibiotics for self-
protection against Gram-negative colonization, we 
designed and synthesized three MIN derivatives. 
Conjugation of long hydrophilic PEG spacers with MIN 
at the C9 position resulted in dramatic loss of 
bioactivity, which argued against the utility of 
permanent linkage of MIN to the surface of medical 
implants by PEG spacers. 
 
Knowing that 9-hydrazino-Ac-NH-MIN showed 
reasonable antibiotic activity, we attached it to the 
surfaces of polystyrene beads and Ti6Al4V foils by an 
acid-labile hydrazone bond that would permit release of 
free 9-hydrazino-Ac-NH-MIN to enter bacteria, 
triggered by bacterial acidification of the implant 
microenvironment. The release kinetics showed a clear 
difference between the rates of 9-hydrazino-Ac-NH-
MIN released at pH 7.4 and pH 5.0. However, the 
hydrazone bond may not be stable enough for long term 
medical implant application. We are also considering 
methylmaleimide31 linkers to enable this strategy. 
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